Equities Analysts Issue Forecasts for RNTX Q1 Earnings

Rein Therapeutics Inc. (NASDAQ:RNTX) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Rein Therapeutics in a research note issued on Thursday, April 2nd. HC Wainwright analyst B. Folkes expects that the company will post earnings of ($0.49) per share for the quarter. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Rein Therapeutics’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS and FY2030 earnings at $0.43 EPS.

A number of other research analysts also recently commented on the stock. downgraded shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. Citigroup downgraded shares of Rein Therapeutics to a “hold” rating in a research note on Wednesday, January 21st. Finally, Wall Street Zen lowered Rein Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 14th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Rein Therapeutics presently has an average rating of “Hold” and an average price target of $8.00.

Rein Therapeutics Stock Performance

Shares of NASDAQ:RNTX opened at $1.21 on Friday. The company has a market capitalization of $33.93 million, a PE ratio of -0.62 and a beta of 1.40. Rein Therapeutics has a twelve month low of $1.02 and a twelve month high of $2.40. The firm has a 50 day simple moving average of $1.25 and a 200-day simple moving average of $1.30.

Rein Therapeutics (NASDAQ:RNTX) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.12).

Institutional Trading of Rein Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Gleason Group Inc. purchased a new position in shares of Rein Therapeutics in the 3rd quarter valued at approximately $26,000. Susquehanna International Group LLP purchased a new stake in shares of Rein Therapeutics during the third quarter worth approximately $35,000. HRT Financial LP purchased a new stake in shares of Rein Therapeutics during the fourth quarter worth approximately $38,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Rein Therapeutics during the second quarter worth $68,000. Finally, Jane Street Group LLC acquired a new stake in shares of Rein Therapeutics during the fourth quarter worth $72,000. 90.89% of the stock is owned by institutional investors and hedge funds.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.